These findings warrant the determination of KIT/PDGFRA status in NF1-GISTs and adjuvant imatinib treatment must be discussed at a multidisciplinary tumor board regarding high-risk KIT or non-p.D842V PDGFRA-mutated NF1-GISTs. This evidence concerns the gene PDGFRA and neoplasm.